Products For Cystic Fibrosis, VWD & Schizophrenia Nearing End Of EU Review
Executive Summary
The European Medicines Agency's CHMP is expected this week to adopt Lists of Outstanding Issues on products for von Willebrand disease, cystic fibrosis and schizophrenia.